Rezdiffra (Resmetirom) Shows Sustained Benefits in MASH Cirrhosis Over Two Years

As reported on Healio, new findings presented at The Liver Meeting highlight the potential of resmetirom (Rezdiffra, Madrigal Pharmaceuticals) in managing metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis—a population with…

Continue Reading Rezdiffra (Resmetirom) Shows Sustained Benefits in MASH Cirrhosis Over Two Years